Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression PatientsBenzinga • 12/01/21
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDDBusiness Wire • 12/01/21
Is it too late to sell Biogen stock after losing an appeal on its multiple sclerosis drug?Invezz • 11/30/21
Biogen shares slide 4% after EU advisory committee says it can't agree to endorse company's Alzheimer's disease drugMarket Watch • 11/17/21
Biogen Stock Is Dropping After a Key Executive Announced His Retirement Amid Alzheimer's Drug StumblesBarrons • 11/16/21
The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple SclerosisGlobeNewsWire • 11/16/21
Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & DevelopmentGlobeNewsWire • 11/16/21
Biogen Sets Industry Record with Recognition on Dow Jones Sustainability World Index for 9th Consecutive YearGlobeNewsWire • 11/15/21
New Phase 3 Data Show Positive Correlation Between ADUHELM™ Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer's DiseaseGlobeNewsWire • 11/11/21
Eisai Presents New Analysis Of Lecanemab Clinical Efficacy Results From Phase 2b Study At Clinical Trials On Alzheimer's Disease (CTAD) ConferencePRNewsWire • 11/11/21
Hit By Slow Rollout, Biogen's Aduhelm Could Soon Find Itself In Price Competition: ReutersBenzinga • 11/10/21